



Press release  
11 June 2024

## **Presentation at the 2nd Annual Spinal Cord Injury Investor Symposium**

Kringle Pharma, Inc. (Head office located in Osaka, Japan; “KRINGLE”), a late clinical-stage biopharmaceutical company, today announces that Kiichi Adachi, President & CEO, will give a presentation on the current status and future prospects of drug development of oremepelmin alfa (recombinant human HGF protein) for the acute phase of spinal cord injury at the 2nd Annual Spinal Cord Injury Investor Symposium (June 26 & 27, 2024 in San Diego, California, U.S.). The presentation is scheduled as follows:

Date: June 27, 2024      14:15-14:30 (PDT)      Presentation  
   14:30-15:15 (PDT)      Panel and Q&A Session  
Place: Sanford Consortium for Regenerative Medicine, Roth Auditorium in La Jolla  
Title: Oremepermin alfa as a novel therapeutic agent for the treatment of acute spinal cord injury

This symposium on spinal cord injury is co-presented by the Christopher and Dana Reeve Foundation, the California Institute for Regenerative Medicine (CIRM) and Lineage Cell Therapeutics, Inc. Pharmaceutical and biotech companies, investors, patient groups, researchers, and medical experts interested in spinal cord injury research and treatment development will gather to discuss the latest research and development advances and business opportunities.

For more information, please visit the symposium website. <https://scisymposium.com/>

### ***About Oremepermin Alfa***

Olemepermin alfa is the generic pharmaceutical name for recombinant human hepatocyte growth factor (HGF) developed by Kringle Pharma. Olemepermin alfa is a glycoprotein (molecular weight: approximately 84,000) consisting of 692 amino acid residues and is produced by CHO cells.

HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs. HGF exerts neurotrophic effects and enhances neurite outgrowth, and the therapeutic effects of HGF on spinal cord injury has been demonstrated in animal models by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine. Expectations for HGF as a novel therapeutic agent are increasing for spinal cord injury.

### ***About Kringle Pharma, Inc.*** <https://www.kringle-pharma.com/en/>

Kringle Pharma is a late clinical-stage biopharmaceutical company established in December 2001 to develop novel biologics based on HGF. Currently, in the late-stage pipeline of oremepermine alfa, the development for acute spinal cord injury has completed Phase 3 clinical trial, and the development for vocal cord scarring is in Phase 3 clinical trial. Kringle’s mission is to contribute to societal and global healthcare through the continued research, development, and commercialization of HGF drug for patients suffering from incurable diseases.



Kringle  
Pharma

**For more information, please contact:**

Kiichi Adachi

President & CEO, Member of the Board

Kringle Pharma, Inc.

☎ +81-72-641-8739

✉ [kpinfo@kringle-pharma.com](mailto:kpinfo@kringle-pharma.com)